82 results
Page 3 of 5
8-K
EX-99.1
zq1 sl0bfa6qs
7 Jan 21
Entry into a Material Definitive Agreement
7:08am
8-K
81f18di et3
7 Jan 21
Entry into a Material Definitive Agreement
7:08am
8-K
EX-99.1
5iwf7lxgtx5rhvcsb3hq
27 Oct 20
Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, a targeted C3 therapy
7:17am
8-K
EX-99.1
gv4fj
7 May 20
Apellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes
7:44am
8-K
nz87fd14
7 May 20
Apellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes
7:44am
8-K
EX-99.1
ckcfrfneex9gbbek2c4
9 Jan 20
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5:22pm
8-K
2zez2j l1ly2p
9 Jan 20
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5:22pm
8-K
k65onhtl3knjp morbj
7 Jan 20
Results of Operations and Financial Condition
4:21pm
8-K
EX-10.1
enqcgay
7 Oct 19
Departure of Directors or Certain Officers
4:06pm
8-K
12qdgjej8nik
16 Sep 19
Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes
5:17pm
8-K
EX-99.1
vxgu5red4txnlrj6 h5d
16 Sep 19
Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes
5:17pm
8-K
EX-99.1
wuiogjupbvsnofbv45sb
12 Sep 19
Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes
8:34am
8-K
lobpz9ro3i2n05 vdq
12 Sep 19
Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes
8:34am
8-K
223g028o49cqke7 n4n5
11 Sep 19
Apellis Pharmaceuticals Announces Proposed Private Offering of
5:13pm
8-K
EX-99.1
f9lowzf1e0dymrfeogy
11 Sep 19
Apellis Pharmaceuticals Announces Proposed Private Offering of
5:13pm